Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
CARv3-TEAM-E T Cells in Glioblastoma
What the film says
Glioblastoma almost always returns. Part of the reason: the tumor is a patchwork. Kill the cells with one marker, and the rest grow on.
The idea: an immune cell that attacks two targets at once.
A patient's own T cells are fitted with a receptor for EGFRvIII, a mutant protein found only on tumor cells. The same cells also secrete a small antibody that grabs normal EGFR, common across glioblastoma, and pulls other T cells in to attack it. They go through a reservoir into the fluid around the brain.
In the first three patients, tumors shrank within days, though for two it did not last.
INCIPIENT, at Mass General with William Curry, now asks about dose and safety. Public record; not medical advice.
Sources behind this film
O'Rourke DM. Sci Transl Med, 2017
Most common adult brain cancer; almost always returns; heterogeneous ("patchwork")
Most common adult brain cancer; almost always returns; heterogeneous ("patchwork")
Choi BD. N Engl J Med, 2024
Receptor for EGFRvIII (tumor-specific) plus secreted T-cell-engaging antibody against wild-type EGFR; Infused through a reservoir into the fluid around the brain; First three patients: rapid regression within days; transient in two of three; no adverse events above grade 3
Infused through a reservoir into the fluid around the brain; INCIPIENT at Mass General with William Curry; dose and safety
The drug
Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
This is a non-randomized, open label, single site Phase 1 study to define the appropriate dose of CARv3-TEAM-E and evaluate its safety for the treatment of recurrent or newly diagnosed glioblastoma. The U.S. Food and Drug Administration (FDA) has not approved CARv3-TEAM-E T Cells as a treatment for any disease. This is the first time that CARv3-TEAM-E T Cells will be given to humans.
CARv3-TEAM-E T Cells are made from a person's own collected immune cells (T-Cells) that are genetically changed and then delivered back into the body to try to kill their cancerous cells. The research study procedures include screening for eligibility, study treatment, including evaluations and follow up visits, blood collections, echocardiograms, and radiologic imaging of tumors. It is expected participants will receive treatment over a period of short-term (approx.
The study
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.